Compare FMC Corp (FMC) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs Moderna, Inc. — how do they compare? FMC Corp trades at $8.3 (market cap $1.39B), while Moderna, Inc. trades at $224.94 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 56.6× FMC Corp's market cap, and FMC Corp pays a 3.59% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold FMC Corp for 68 Days and Moderna, Inc. for 59 Days on average.
| FMC | MRNA | |
|---|---|---|
Market Cap | $1.39B | $78.65B |
Volume | 4,145,979 | 37,373,437 |
Sector | Basic Materials | Health |
52-Week High | $30.63 | $203.46 |
52-Week Low | $8.44 | $22.36 |
Typical Hold Time | 68 Days | 59 Days |
Enterprise Value | $5.19B | $74.80B |
Dividend Yield | 3.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC trades at $8.36, down 8.03% in the past 24 hours, reflecting bearish technical signals and weak profitability. The company reported a net loss of -$2.24B in 2025, with negative margins and declining revenue. Recent news includes a regulatory filing for rimisoxafen in Brazil and a minority equity investment by Tessenderlo Group. Cash flow trends show volatility, with 2025 net cash flow positive at $227M but driven by financing activities.
The outlook remains challenging due to persistent losses and high debt, though analyst consensus suggests upside with a $14.60 price target. Key risks include execution on deleveraging, cyclical industry pressures, and competitive threats. Investment opportunity hinges on successful turnaround efforts and new product approvals.
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
